Credit: Shutterstock photo(RTTNews.com) - The U.S. Food and Drug Administration has approved VAXELIS for use in children from 6 weeks through 4 years of age (prior to the 5th birthday). Vaxelis was developed as part of a joint-partnership between Sanofi and Merck & Co ( MRK ).
VAXELIS is Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine.
Sanofi and Merck are working to maximize production of VAXELIS to allow for a sustainable supply to meet anticipated U.S. demand. Commercial supply will not be available in the U.S. prior to 2020.
Vaxelis is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b. VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).
Read the original article on RTTNews (http://www.rttnews.com/2965483/fda-approves-sanofi-and-merck-s-pediatric-hexavalent-combination-vaccine-vaxelis.aspx)
For comments and feedback: contact editorial@rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
